These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9466320)

  • 1. Histopathological improvement of acromegalic cardiomyopathy by intermittent subcutaneous infusion of octreotide.
    Nishiki M; Murakami Y; Sohmiya M; Koshimura K; Inoue K; Goto Y; Nakamura N; Kato Y
    Endocr J; 1997 Oct; 44(5):655-60. PubMed ID: 9466320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery.
    Legrand V; Beckers A; Pham VT; Demoulin JC; Stevenaert A
    Eur Heart J; 1994 Sep; 15(9):1286-9. PubMed ID: 7982434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dilated cardiomyopathy in a patient with acromegaly: echocardiographic development after treatment].
    Gómez-Barrado JJ; Turégano S; Marcos G; Porras Y
    Rev Esp Cardiol; 2007 Feb; 60(2):213-4. PubMed ID: 17338889
    [No Abstract]   [Full Text] [Related]  

  • 5. Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy.
    Hwang MW; Shimatsu A; Sasaki Y; Ayukawa H; Inenaga K; Takeoka R; Iwase T; Kawai C
    Heart Vessels; 2007 May; 22(3):202-7. PubMed ID: 17533526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995).
    Caron P; Cogne M; Gusthiot-Joudet B; Wakim S; Catus F; Bayard F
    Eur J Endocrinol; 1995 Mar; 132(3):320-5. PubMed ID: 7889181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of juvenile acromegaly that was initially diagnosed as severe congestive heart failure from acromegaly-induced dilated cardiomyopathy.
    Sue M; Yoshihara A; Okubo Y; Ishikawa M; Ando Y; Hiroi N; Shibuya K; Yoshino G
    Intern Med; 2010; 49(19):2117-21. PubMed ID: 20930439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
    J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is growth hormone good for the heart?
    Silverman BL; Friedlander JR
    J Pediatr; 1997 Jul; 131(1 Pt 2):S70-4. PubMed ID: 9255233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart transplantation for terminal congestive heart failure in an acromegalic patient.
    Albat B; Leclercq F; Serre I; Fille A; Baldet P; Grolleau-Raoux R; Thevenet A
    Eur Heart J; 1993 Nov; 14(11):1572-5. PubMed ID: 8299642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous versus intermittent subcutaneous infusion of octreotide in the treatment of acromegaly.
    Harris AG; Kokoris SP; Ezzat S
    J Clin Pharmacol; 1995 Jan; 35(1):59-71. PubMed ID: 7751414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide improved ventricular arrhythmia in an acromegalic patient.
    Suyama K; Uchida D; Tanaka T; Saito J; Noguchi Y; Nakamura S; Tatsuno I; Saito Y; Saeki N
    Endocr J; 2000 Mar; 47 Suppl():S73-5. PubMed ID: 10890189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide.
    Li JK; Chow CC; Yeung VT; Mak TW; Ko GT; Swaminathan R; Chan JC; Cockram CS
    Aust N Z J Med; 2000 Aug; 30(4):457-61. PubMed ID: 10985510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of octreotide in dilated cardiomyopathy: an open-label trial in 12 patients.
    Eryol NK; Güven M; Topsakal R; Sungur M; Ozdogru I; Inanç T; Oguzhan A
    Jpn Heart J; 2004 Jul; 45(4):613-21. PubMed ID: 15353872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dilated cardiomyopathy in acromegaly worsening under octreotide treatment. Apropos of a case].
    Leclercq F; Fille A; Albat B; Beigbeder JY; Messner P; Thévenet A; Bringer J; Grolleau R
    Ann Cardiol Angeiol (Paris); 1993 Mar; 42(3):151-4. PubMed ID: 8498802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide.
    Avagnina P; Martini M; Terzolo M; Sansoé G; Peretti P; Tinivella M; Pia A; Molino G; Angeli A
    Metabolism; 1996 Jan; 45(1):109-13. PubMed ID: 8544766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure.
    Shimakura A; Miyakoshi H; Ohkuwa H; Kitabayashi M; Komai T; Hisada A; Aoki K; Sakagami S; Kobayashi K; Takata S
    Jpn Heart J; 2002 Jan; 43(1):69-77. PubMed ID: 12041892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.